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Abstract 43 
Disseminated infections with the fungal species Cryptococcus neoformans or, less 44 
frequently, C. gattii, are an important cause of mortality in immunocompromised 45 
individuals. Central to the virulence of both species is an elaborate polysaccharide 46 
capsule that consists predominantly of glucuronoxylomannan (GXM). Due to its 47 
abundance, GXM is an ideal target for host antibodies, and several monoclonal 48 
antibodies (mAbs) have previously been derived using purified GXM or whole 49 
capsular preparations as antigen. In addition to their application in the diagnosis of 50 
cryptococcosis, anti-GXM mAbs are invaluable tools for studying capsule structure. 51 
In this study, we report the production and characterisation of a novel anti-GXM 52 
mAb, Crp127, that unexpectedly reveals a role for GXM remodelling during the 53 
process of fungal Titanisation. We show that Crp127 recognises a GXM epitope in 54 
an O-acetylation dependent, but xylosylation-independent, manner. The epitope is 55 
differentially expressed by the four main serotypes of Cryptococcus neoformans and 56 
gattii, is heterogeneously expressed within clonal populations of C. gattii serotype B 57 
strains and is typically confined to the central region of the enlarged capsule. 58 
Uniquely, however, this epitope redistributes to the capsular surface in Titan cells, a 59 
recently characterised morphotype where haploid 5 m cells convert to highly 60 
polyploid cells >10 m with distinct but poorly understood capsular characteristics. 61 
Titans are produced in the host lung and critical for successful infection. Crp127 62 
therefore advances our understanding of cryptococcal morphological change and 63 
may hold significant potential as a tool to differentially identify cryptococcal strains 64 
and subtypes.   65 
 66 
Introduction 67 
As the two main etiological agents of cryptococcosis, Cryptococcus neoformans and 68 
Cryptococcus gattii are major contributors to the global health burden imposed by 69 
invasive fungal infections (1). Whilst C. neoformans typically manifests as meningitis 70 
in immunocompromised individuals, C. gattii infections are not associated with 71 
specific immune defects and have been responsible for fatal outbreaks of pneumonia 72 
(2–4). Central to the virulence of both species is an elaborate polysaccharide 73 
capsule, without which Cryptococcus is rendered avirulent (5, 6). The composition of 74 
this capsule is highly variable and differs between yeast cells and Titan cells (defined 75 
as cells >10 m in cell body diameter with increased ploidy and altered cell wall and 76 
capsule) formed by C. neoformans within the host lung (7–9). Titan cells contribute 77 
to pathogenesis by resisting phagocytosis, enhancing dissemination of yeast to the 78 
central nervous system and altering host immune status (7, 9–13). 79 
 80 
The cryptococcal capsule consists of ~90% glucuronoxylomannan (GXM), ~10% 81 
glucuronoxylomannogalactan (GXMGal) and <1% mannoproteins (MPs) (14). GXM 82 
is a megadalton polysaccharide containing a backbone of -(1,3)-mannan that is 83 
decorated with -(1,2)-glucuronic acid, -(1,2)-xylose and -(1,4)-xylose substituents 84 
(15). The backbone mannan can also be O-acetylated, although the position at 85 
which this modification is added remains unclear for most strains (14–16). Seven 86 
repeat motifs – called structure reporter groups (SRGs) – contribute to structural 87 
variation in GXM (15). All SRGs contain a -(1,2)-glucuronic acid on their first 88 
mannose residue, however the number of -(1,2)- and -(1,4)-xylose substituents 89 
varies (15). The extent and position of O-acetyl groups in each SRG remain unclear, 90 
however xylose and O-acetyl groups attached to the same mannose residue appear 91 
to be mutually exclusive (17). SRG usage differs between the four main serotypes of 92 
Cryptococcus, with each strain designated a serotype based on the reactivity of its 93 
capsular material with antibody preparations (18). C. neoformans serotypes A and D 94 
tend to biosynthesise GXM containing SRGs with fewer xylose substituents than 95 
those from C. gattii serotypes B and C (15, 19). 96 
 97 
Whilst capsule structure differs between serotypes of Cryptococcus, a flexible 98 
biosynthetic pathway enables rapid remodelling of the capsule under different 99 
environmental conditions (20). In vitro, changes in O-acetylation have been 100 
associated with cell ageing in C. neoformans (21), reaffirming earlier reports that 101 
capsules produced within clonal populations are far from homogeneous (19, 22). In 102 
vivo, changes in capsule size and structure coincide with the infection of different 103 
organs and likely enhance fitness through the evasion of host immunity (23–25). In 104 
light of these observations, it is perhaps unsurprising that capsules produced by 105 
Titan cells are structurally distinct from those produced by typical yeast cells (7, 11, 106 
26). As the increased chitin content of cell walls produced by Titan cells is 107 
associated with activation of a detrimental TH2 immune response during 108 
cryptococcosis (27), it is possible that hitherto unidentified structural differences in 109 
Titan cell capsules also contribute to the modulation of host immunity by this C. 110 
neoformans morphotype.  111 
 112 
Alterations in capsule structure are likely to affect how Cryptococcus is perceived by 113 
host immune molecules, with antibodies particularly sensitive to small changes in 114 
molecular structures. Following exposure to cryptococci, immunoglobulin M (IgM) 115 
antibodies are the most abundant isotype of antibody produced in response to GXM 116 
(28). As a repetitive capsular polysaccharide, GXM is a T-independent type 2 117 
antigen and antibodies generated against it utilise a restricted set of variable region 118 
gene segments (29). Using monoclonal antibodies (mAbs) in conjunction with 119 
mutants harbouring specific defects in GXM modification (17, 30, 31), it has been 120 
determined that O-acetylation and, to a lesser extent, xylosylation of GXM are 121 
important for epitope recognition by anti-GXM antibodies (16, 30). Whilst there is no 122 
consensus surrounding the effect of GXM O-acetylation on virulence (17, 32), its 123 
influence on antibody binding suggests that changes in GXM O-acetylation could be 124 
a strategy deployed by cryptococci to avoid recognition by immune effectors. 125 
Additionally, despite the immunomodulatory roles for GXM O-acetylation that have 126 
been identified (30, 33), receptors that bind O-acetylated GXM remain elusive (34). 127 
Due to the enigmatic nature of this modification within the primary virulence factor of 128 
cryptococci, further investigation of GXM O-acetylation will help unravel the 129 
complexities of cryptococcal capsule structure with the ultimate aim of understanding 130 
the strategies deployed by this fatal fungal pathogen to evade host immunity.   131 
 132 
In the present study, we report the generation of Crp127, a murine IgM mAb, using a 133 
cocktail of heat-killed C. neoformans H99 (serotype A) (35) heat-killed C. gattii R265 134 
(serotype B) (36) and their lysates as an immunogen. Characterisation of Crp127 135 
demonstrated that it is an O-acetyl-dependent anti-GXM mAb specific to an epitope 136 
expressed by the four Cryptococcus serotypes in a serotype-specific manner. Having 137 
subsequently found that this epitope is heterogeneously expressed within serotype B 138 
populations and is spatially confined to distinct regions of the enlarged capsule 139 
across all strains tested, we then turned our attention to its expression by Titan cells. 140 
Intriguingly, we noticed that the spatial distribution of this epitope differs within the 141 
capsules produced by the three C. neoformans morphotypes found within Titanising 142 
populations. Further analysis revealed that, under conditions permissive for 143 
Titanisation, cell enlargement coincides with the gradual redistribution of this epitope 144 
to the capsule surface. 145 
 146 
Results 147 
Crp127 recognises a capsular epitope located in GXM 148 
During hybridoma screening, Crp127 was identified as staining the outer zone of live 149 
cryptococci. We first assessed whether Crp127 recognises a capsular component by 150 
performing flow cytometric analysis of three GXM-deficient mutants (R265 cap10 151 
(37), KN99 cap59 (38) and B3501 cap67 (39)), a GXMGal-deficient mutant 152 
(KN99 uge1 (38)) and a mutant lacking both GXM and GXMGal (KN99 153 
cap59uge1 (38)), using an Alexa-488-conjugated anti-IgM secondary antibody to 154 
label Crp127. Unlike their corresponding wild-type strains, the GXM-deficient 155 
mutants were not recognised by Crp127 (fig. 1A-C; cap10 P < 0.05; cap67 P < 156 
0.01; cap59 P < 0.01; cap59uge1 P < 0.01, Student’s t-test). In contrast, the 157 
GXMGal-deficient uge1 mutant was bound at levels similar to the wild-type strain 158 
(fig. 1C; P > 0.05). Confocal microscopy corroborated these observations, with no 159 
observable binding of Crp127 to GXM-deficient mutants but clear binding of Crp127 160 
to the GXMGal-deficient mutant (fig. 1D-F). Taken together, these experiments 161 
demonstrated that the epitope recognised by Crp127 – hereon referred to as the 162 
Crp127 epitope – is a component of GXM.  163 
 164 
GXM O-acetylation is required for Crp127 epitope recognition  165 
Considering the importance of O-acetylation and xylosylation to the antigenic 166 
signature of GXM (30), we proceeded to investigate the effect of these modifications 167 
on Crp127 epitope recognition. We firstly tested the ability of Crp127 to recognise 168 
two xylose-deficient mutants (JEC155 uxs1 (serotype D) (41) and KN99 uxs1 169 
(serotype A) (38)). No significant differences were found between either uxs1 170 
mutant and their corresponding wild-type strains (fig. 2A; JEC155 uxs1 P > 0.05; 171 
KN99 uxs1 P > 0.05), indicating that xylosylation does not impact Crp127 binding. 172 
In contrast, however, antibody binding was completely abrogated in the O-acetyl-173 
deficient cas1 mutant (fig. 2B; P < 0.01), indicating that O-acetylation of GXM is an 174 
essential prerequisite for Crp127 epitope recognition.  175 
 176 
Having made this observation, we proceeded to test two further mutants in genes 177 
implicated in GXM O-acetylation. KN99 cas3 exhibits a ~70% reduction in GXM 178 
O-acetylation, whereas KN99 cas31 exhibits subtle differences in sugar 179 
composition of GXM but no reduction in GXM O-acetylation (42). Binding of Crp127 180 
to the cas3 mutant was slightly reduced but statistically to the wild-type strain (fig. 181 
2C; P > 0.05). This may reflect reduced density of O-acetylation in GXM produced by 182 
this mutant.  Surprisingly, however, Crp127 completely failed to recognise the 183 
cas31 mutant despite this strain retaining an O-acetylation profile similar to the 184 
wild-type (42) (fig. 2C; P < 0.01). To be certain that the O-acetyl-defective mutants 185 
tested still produced capsule, we confirmed the binding of O-acetyl-independent anti-186 
GXM mAb F12D2 (43, 44) to each strain (fig. 2K). Thus, CAS1 and CAS31 187 
contribute to the formation of an O-acetylation dependent Crp127 epitope. 188 
 189 
Cryptococcus serotypes differ in their level of Crp127 epitope recognition 190 
Differences in the O-acetylation state of GXM contributes towards serotype 191 
classification and is a source of structural variation within the capsule of cells from a 192 
clonal population (21, 30). Therefore, with Crp127 recognising an O-acetyl-193 
dependent epitope, we next checked for differences in Crp127 staining between the 194 
five recognised serotypes of Cryptococcus neoformans and gattii, testing two 195 
independent strains of each serotype. Flow cytometry analysis demonstrated that 196 
Crp127 consistently bound most effectively to serotype D strains (B3501 and 197 
JEC155) (fig. 3A-B), with all cells within these populations exhibiting high-level 198 
accessibility of the Crp127 epitope (fig. 3F). We detected slightly lower binding to 199 
serotype A strains (fig. 3A-B), with high-level homogeneous staining also seen in the 200 
case of H99, but a proportion of unstained cells from strain KN99 (fig. 3C).  201 
Interesting, the two AD hybrid strains tested (CBS 950 (47) and ZG287 (48)) were 202 
notably different in regard to Crp127 binding (fig. 3A-B), with CBS 950 exhibiting low-203 
level heterogeneous staining and ZG287 showing high-level homogeneous staining 204 
(fig. 3G). 205 
 206 
The two remaining cryptococcal serotypes, B and C, together represent C. gattii.  207 
Serotype B strains R265 and CDCR272 (36) demonstrated significantly lower 208 
epitope recognition than C. neoformans serotypes (fig. 3A-B) and considerable 209 
heterogeneity within the population (fig. 3D). Interestingly, however, serotype C 210 
strains were completely unrecognised by Crp127, with neither strain CBS 10101 (49) 211 
or M27055 (50) showing detectable staining (fig. 3A, B and E). From this, we 212 
conclude that there are serotype-specific differences in the availability of the Crp127 213 
epitope, with epitope accessibility being related to serotype in a pattern of D > A >> 214 
B >>> C.    215 
 216 
Crp127 exhibits serotype-specific binding patterns that are not associated with 217 
opsonic efficacy 218 
Having identified differential levels of the Crp127 epitope between serotypes using 219 
flow cytometry, we next examined their patterns of binding by immunofluorescence 220 
microscopy. Indirect immunofluorescence revealed an annular binding pattern for all 221 
four strains representing serotypes A and D (fig. 4A and D). In line with their 222 
differences in flow cytometry, the two AD hybrid strains tested showed different 223 
patterns of binding, with CBS 950 showing punctate binding and ZG287 showing a 224 
mix of annular and punctate staining. Both C. gattii serotype B strains exhibited 225 
punctate binding (fig. 4B and E) whilst, in agreement with flow cytometry, no Crp127 226 
binding was detected when imaging serotype C strains CBS 10101 or M27055. 227 
However, O-acetyl-independent mAb F12D2 bound well to these strains, suggesting 228 
that the lack of Crp127 binding reflects changes in GXM O-acetylation rather than 229 
loss of capsular material (fig. 4F).  230 
 231 
As annular and punctate binding patterns have been associated with opsonic and 232 
non-opsonic anti-GXM IgM mAbs, respectively, we tested the ability of Crp127 to 233 
opsonise cells from strains KN99 (annular) and R265 (punctate). Unlike positive 234 
control treatments mAb 18B7 and pooled human serum, Crp127 did not enhance 235 
phagocytosis of either strain by J774 macrophage-like cells in the presence or 236 
absence of serum (fig. S2). In summary, annular binding patterns are associated 237 
with the high-level binding of Crp127 to C. neoformans serotypes A and D strains. 238 
On the other hand, punctate binding is associated with low-level binding of Crp127 to 239 
serotype B strains. However, under the conditions tested in this study, neither 240 
binding pattern is clearly associated with opsonic efficacy.  241 
 242 
Crp127 epitope recognition reflects serotype differences within C. gattii 243 
Our data above indicate that Crp127 binding accurately reflects known serotyping of 244 
cryptococcal strains. However, recent genomic data indicate that C. gattii may in fact 245 
be composed of several cryptic species (51). We therefore extended our analysis of 246 
this species group by investigating a further four C. gattii strains, representing 247 
molecular subtypes VGI-VGIII. Similar levels of Crp127 epitope recognition was seen 248 
for serotype B strains R265 (VGIIa), CDCR272 (VGIIb), EJB55 (VGIIc) (52) and 249 
CA1873 (VGIIIa) (53) (fig. 5A-B; P > 0.05), however significantly higher recognition 250 
was seen for the serotype B strain DSX (VGI) (54) (fig. 5A-B; P < 0.01). Indirect 251 
immunofluorescence corroborated these findings, with punctate binding seen for the 252 
four strains presenting the epitope at low levels (fig. 5D-H) and annular binding seen 253 
for strain DSX (fig. 5C). We also tested strain CA1508 (VGIIIb) (55), a C. gattii strain 254 
that, to our knowledge, has not previously been serotyped. Both flow cytometry and 255 
indirect immunofluorescence showed that Crp127 did not recognise this strain (fig. 256 
5A and H), implying that it is a serotype C strain. In combination with the data 257 
presented in figure 3, our finding that four out of five serotype B strains were bound 258 
similarly by Crp127 suggests that availability of this epitope is fairly well conserved 259 
within this serotype.  260 
 261 
The Crp127 epitope localises to spatially confined zones of the enlarged 262 
capsule and binding elicits capsular swelling reactions  263 
Having investigated the binding of Crp127 to cells with a small capsule, we next 264 
wished to investigate cells that had been grown in capsule-inducing conditions, given 265 
that capsule enlargement occurs shortly after infection of the host. Interestingly, in all 266 
of the strains tested we saw that the Crp127 epitope was spatially confined to distinct 267 
capsular regions (fig. 6). For serotype A strains H99, KN99 (fig. 6A), and CBS 8336 268 
(56) (fig. S3F) and serotype D JEC21 and B3501 (fig. 6D) strains, antibody binding 269 
was detected in the central zone of the capsule. Serotype B strains differed, with 270 
regions adjacent to the cell wall and on the capsule surface bound by Crp127 in the 271 
case of strain R265 but only the single region proximal to the surface bound in the 272 
case of CDCR272 (fig. 6B). Serotype AD strain ZG287 exhibited a similar pattern of 273 
binding to R265, with Crp127 binding to both an inner and outer region of the 274 
capsule, however strain CBS 950 was bound in a region adjacent to the cell wall (fig. 275 
6D). 276 
 277 
The binding of mAbs to capsular GXM alters the refractive index of the enlarged 278 
capsule, resulting in capsular swelling reactions that can be visualised using DIC 279 
microscopy (57). In testing the ability of Crp127 to produce a capsular swelling 280 
reaction with strains KN99, R265, B3501 and CBS 950, we observed no discernible 281 
differences in the reaction pattern produced between strains, with a highly refractive 282 
outer rim and a textured inner capsule characteristic for each strain (fig. 6E-H; 283 
bottom panels). Notably, however, Crp127 reaction patterns differed from those 284 
elicited by 18B7, which also exhibited a highly refractive outer rim but lacked texture 285 
throughout the capsule (fig. 6E-H; top right panels). Taken together, our studies of 286 
Crp127 binding to capsule-induced cells demonstrate that the Crp127 epitope is 287 
localised to specific capsular regions and that Crp127 binding produces capsular 288 
swelling reactions that are independent of serotype.   289 
 290 
Spatial distribution of the Crp127 epitope differs within the capsules produced 291 
by Titanide, yeast-like and Titan cells 292 
Following infection of the host lung, a proportion of C. neoformans cells differentiate 293 
into Titan cells, a very large morphotype that facilitates pathogenesis and is 294 
associated with poor clinical outcomes (8, 12). When grown under Titanising 295 
conditions in vitro, C. neoformans forms a heterogeneous population of small, oval-296 
shaped Titanide cells (thin-walled cells 2-4 m in diameter that are distinct from 297 
thick-walled 1 m micro-cells), yeast-like cells (~5 m) and large Titan cells (>10 m) 298 
(9, 58). As differences in capsule are known to exist between yeast and Titan cells 299 
(26, 59), we tested whether Crp127 could distinguish the morphological subtypes 300 
found in Titanising populations from strains H99 and KN99, two closely-related 301 
strains for which Titanisation has been extensively studied (7, 9, 11, 26, 60). Indeed, 302 
when these strains were grown under Titanising conditions in vitro and imaged, we 303 
noticed differences in the spatial distribution of the Crp127 epitope within the 304 
capsules produced by cells of different sizes (fig. 7A and fig. S3A). Cells 2-4 m 305 
were poorly recognised by Crp127 (fig. 7A), suggesting these cells did not produce 306 
the epitope or that they were had budded after the immunostaining procedure. 307 
Crp127 bound to a capsular region adjacent to the cell wall in smaller yeast cells, 308 
within the central zone of the capsule in larger yeast-like cells and close to the 309 
capsule surface of Titan cells (fig. 7A and fig. S3A). In order to quantify how cell size 310 
affects capsular distribution of the Crp127 epitope, we determined the ratio between 311 
the area of capsule encompassed by the Crp127 epitope and the area of the whole 312 
capsule; using this metric, a ratio approaching 1 is indicative of the epitope being 313 
found in close proximity to the capsule surface (fig. 7B).  Across three biological 314 
repeats (with a mean number of 111 and 133 cells measured for strains H99 and 315 
KN99, respectively), mean ( standard error of the mean) ratios of 0.07  0.02 and 316 
0.05  0.02 were calculated for cells 2-4 m in diameter for strains H99 and KN99, 317 
respectively, consistent with our initial observations that Crp127 bound near to the 318 
cell wall or not at all in the smallest cells (fig. 7C and fig. S3B). For cells 4-10 m, 319 
mean ratios were 0.42  0.03 and 0.40  0.01 for strains H99 and KN99, 320 
respectively (fig. 7C and fig. S3B), indicating the Crp127 epitope is predominantly 321 
located in the central zone of the capsule in 4-10 m cells, as we had previously 322 
observed (fig. 6A). Finally, the mean ratios for cells >10 m in diameter were 0.72  323 
0.03 and 0.71  0.03 for strains H99 and KN99 respectively, making them 324 
significantly higher than those calculated for both 2-4 m (fig. 7C and fig. S3B; H99 325 
P < 0.001; KN99 P < 0.001) and 4-10 m cells (fig. 7C and S3B; H99 P < 0.001; 326 
KN99 P < 0.001). In summary, our results demonstrate that Crp127 binds closer to 327 
the capsule surface of Titan cells than Titanide and yeast-like cells in the widely used 328 
serotype A strains H99 and KN99. 329 
 330 
Migration of the Crp127 epitope towards the surface of the capsule coincides 331 
with cell enlargement  332 
To investigate the effect of small changes in cell size on Crp127 epitope distribution, 333 
we plotted cell body diameter against epitope proximity to the capsule surface for all 334 
H99 and KN99 cells measured (fig. 7D and fig. S3C). In doing so, we identified a 335 
positive correlation between cell body diameter and epitope proximity to the capsule 336 
surface of yeast-like cells. In agreement with this, when plotting only cells of cell 337 
body diameter 4-10 m, we found a positive correlation between cell body diameter 338 
and epitope proximity to the capsule surface in both strains tested (fig. 7E and fig. 339 
S3D; H99 r = 0.65; KN99 r = 0.66). Unlike cell body diameter, capsule diameter did 340 
not correlate with epitope proximity to the capsule surface, indicating that changes in 341 
capsule size do not explain changes in the proximity of the Crp127 to the capsule 342 
surface (fig. 7F and fig. S3E).  343 
 344 
Acknowledging the genetic similarities between strains H99 and KN99, we also 345 
investigated serotype A strain CBS 8336 (56), serotype D strain B3501 and serotype 346 
B strain R265.  Previously, a C. gattii strain R265 isolate failed to Titanise in vitro 347 
using the serum induction protocol, but was observed to form <10 m Titan-like cells 348 
using an alternate protocol (9, 60, 61). Using a different source of R265, we were 349 
able to observe limited Titans in this strain using serum induction (Figure S3F). In 350 
addition, C. neoformans strains CBS 8336 and B3501 both formed Titan cells 351 
(Figure S3F). Although Crp127 binding appeared to be redistributed outwards during 352 
Titanisation of CBS 8336 and R265, redistribution was less apparent in the case of 353 
B3501 (fig. S3F). Thus, the extent of epitope redistribution during Titanisation may 354 
vary between strains.  355 
 356 
Our results suggest that, in two strains frequently used for the study of Titanisation, 357 
the Crp127 epitope moves gradually to the capsule surface as cells enlarge, raising 358 
the question of how this may occur. Throughout our imaging experiments, the 359 
binding of Crp127 to the majority of Titanide and yeast-like cells (in addition to all 360 
Titan cells) produced an annular immunofluorescence binding pattern (fig. 7F; top 361 
row). However, we also noticed that some Titanide and yeast-like cells produced a 362 
second more faint ring of Crp127 epitope outside of this typical annular ring (fig. 7F; 363 
bottom row). This may represent the addition of Crp127 epitope closer to the capsule 364 
surface, partially explaining how redistribution of this epitope coincides with cell 365 
enlargement. 366 
 367 
Discussion 368 
In this study, we demonstrated that a capsular epitope recognised by Crp127 – an 369 
anti-GXM mAb produced in our laboratory – contributes to serotype-specific 370 
differences in capsule structure. This epitope traverses the capsule as cells enlarge 371 
under conditions permissive for Titanisation, resulting in its differential distribution 372 
throughout the capsule of the three C. neoformans morphotypes found within 373 
Titanising populations of two strains used to model cryptococcal Titanisation. 374 
Detailing the accessibility and localisation of this epitope adds to the existing body of 375 
literature surrounding the variability of the cryptococcal capsule between strains and 376 
reveals yet another way in which Titan cell capsules are structurally distinct from 377 
those produced by yeast cells (21–23, 32, 62). 378 
 379 
 380 
Based on our examination of a panel of mutants harbouring capsule defects, we 381 
propose that Crp127 is an anti-GXM mAb whose binding depends on GXM O-382 
acetylation, but not xylosylation. When comparing sequences of the CDRs from 383 
Crp127 with four previously characterised anti-GXM IgM mAbs – namely 2D10, 384 
12A1, 13F1 and 21D2 – we found that Crp127 CDRs were significantly different, 385 
particularly with regard to the light-chain variable (VL) CDRs. These differences 386 
reflect differential gene usage and are likely to manifest as differences in epitope 387 
specificity (46, 63). In contrast, when we aligned the heavy-chain variable (VH) and 388 
VL sequences from Crp127 with those from anti-GXM IgG1 mAb 302, we noticed that 389 
the sequences were extremely similar as a result of identical variable region gene 390 
segment usage by these two mAbs. Identical gene segment usage is not entirely 391 
surprising given the restricted set of antibody gene segments utilised by antibodies 392 
specific to capsular polysaccharides (29), however the two mAbs were produced in 393 
response to GXM derived from different serotypes of Cryptococcus. Whereas mAb 394 
302 was generated following the immunisation of a mouse with serotype D GXM 395 
(ATCC 24064) (64), we generated Crp127 through the immunisation of a mouse with 396 
a cocktail containing both serotype A (H99) and serotype B (R265) GXM. Whichever 397 
serotype of GXM activated the B cell from which Crp127 derives, the sequence 398 
similarities between mAbs Crp127 and 302 demonstrate that nearly identical 399 
antibodies can be elicited during infection by at least two different serotypes of 400 
Cryptococcus.  401 
 402 
Crp127 binding shows strong serotype dependence, with serotype D strains being 403 
recognised most strongly, followed by serotype A strains. C. gattii serotype B strains 404 
show lower, heterogeneous Crp127 epitope recognition and a punctate 405 
immunofluorescence binding pattern, whilst serotype C strains entirely fail to bind the 406 
antibody. Interestingly, the predominant SRG found in GXM produced by serotype D, 407 
A, B and C contains 1, 2, 3 and 4 xylose substituents, respectively (15, 65). Together 408 
with the previous observation that -(1,2)-xylose and O-acetyl groups are not added 409 
to the same backbone mannose residue (17, 42), this differential SRG usage may 410 
explain the variable Crp127 epitope recognition in one of two ways. For example, the 411 
additional xylose substituents present in the predominant SRG found in serotype B 412 
and C GXM may prevent addition of O-acetyl groups in such a way that the Crp127 413 
epitope is not formed. Alternatively, the extra xylose substituents found in these 414 
SRGs may sterically hinder binding of Crp127 to its epitope. Studies that further 415 
elucidate the roles of specific proteins in GXM biosynthesis – together with advances 416 
in techniques that enable chemical synthesis of GXM oligosaccharides – will 417 
enhance our understanding of how epitope recognition is achieved by anti-GXM 418 
mAbs like Crp127. Intriguingly, a recent transcriptomics study identified CAS31 as 419 
being absent from the genome of strain CBS 10101 (66), a serotype C isolate that 420 
we subsequently found was not recognised by Crp127. Whilst we cannot rule out the 421 
possibility that other factors contribute to the inability of Crp127 to recognise 422 
serotype C strains, it is tempting to speculate that the loss of CAS31 function in this 423 
lineage may explain its lack of reactivity with Crp127 (32, 34). The molecular basis 424 
for CAS31-dependent epitope recognition remains to be determined, however, the 425 
cas31 has been shown  to harbour minor alterations in GXM xylose composition 426 
(38). Therefore xylosylation may be in competition with O-acetylation at Crp127 427 
target residues (17).  Consistent with this, anti-GXM mAbs CRND-8, 21D2 and 13F1 428 
also fail to recognise cas31 mutants (38), suggesting overall changes in capsule 429 
organisation in this mutant.  430 
 431 
Perhaps our most striking observation regarding the Crp127 epitope was its 432 
differential distribution throughout the capsules produced by Titanide, yeast-like and 433 
Titan cells of strains H99 and KN99. Structural differences in Titan capsule 434 
compared to yeast capsule have been demonstrated previously by SEM and staining 435 
with the anti-capsule antibody 18B7 (7).  Additionally, mAb 18B7 staining of in vivo-436 
derived Titan cells was heterogenous across individual Titans, including annular, 437 
exterior and interior localisations in different cells (7). Using a hypoxic in vitro Titan 438 
induction protocol, Hommel subsequently showed that there were no differences in 439 
localisation of the anti-GXM mAbs E1, 2D10 or 13F1 in Titans compared to yeast 440 
(59). Therefore, the consistent progression in localisation pattern across cell types 441 
shown here appears to be a unique feature of the Crp127 epitope (7). The positive 442 
correlation between cell size and Crp127 epitope proximity to the capsule surface is 443 
suggestive of a scenario whereby the epitope is initially produced in a capsular 444 
region adjacent to the cell wall in small Titanide cells before redistributing first to the 445 
midzone of yeast-like cells and eventually to the capsule surface of Titan cells. This 446 
finding raises the intriguing question of how formation and removal of the Crp127 447 
epitope is so tightly spatially controlled within the capsule. One possibility is that the 448 
epitope could be formed at the cell surface and then move outwards as the capsular 449 
material elongates. Therefore, we speculate that since the epitope moves outwards 450 
at a faster rate than the capsule expands, and since the amount of epitope that 451 
initially surrounds a smaller Titanide or yeast-like cell would not be sufficient to form 452 
the perimeter of capsule encasing a much larger Titan cell, we instead favour a 453 
model in which the epitope is enzymatically removed and added to different regions 454 
of the capsule during growth. For instance, it is possible that GXM decorated with O-455 
acetyl groups is added closer to the capsule surface in larger cells or that such 456 
regions are “unmasked” in a different capsular region as the capsule is reshaped 457 
during Titanisation (26).  458 
 459 
To summarise, our findings demonstrate that the differential distribution of specific 460 
epitopes within the cryptococcal capsule is yet another way in which Titan cells can 461 
be distinguished from canonical yeast cells. We hope that this will prompt further 462 
investigation into how redistribution of capsular epitopes occurs and what impact this 463 
may have on Cryptococcus cell biology. We recently showed that Titanisation is 464 
triggered by exposure to components of the bacterial cell wall (9), whilst interactions 465 
between bacteria and the capsule have previously been described (67, 68). Capsule 466 
also contributes to the buoyancy of Cryptococcus cells (69). As such, the importance 467 
of redistributing capsular epitopes during Titanisation should be considered in the 468 
context of Cryptococcus cell biology in both the environment and during infection. 469 
 470 
 471 
 472 
Materials and methods 473 
Reagents, strains and mAbs 474 
All reagents were purchased from Sigma-Aldrich unless stated otherwise. The 475 
Cryptococcus strains used in this study are described in table S1. The anti-GXM 476 
mAbs used in this study are described in table S2.  477 
 478 
Growth of cryptococci 479 
Cryptococcus strains were preserved at -80C in MicroBankTM tubes (Thermo Fisher 480 
Scientific) prior to being stored on yeast extract peptone dextrose (YPD) agar plates 481 
at 4C for a maximum of 30 days. Unless stated otherwise, strains were cultured on 482 
a rotary wheel at 20 rpm for 24 h at 25C in round-bottom culture tubes containing 3 483 
mL YPD broth. To induce capsule growth, Cryptococcus cells were grown in round-484 
bottom culture tubes containing 3 mL Dulbecco’s Modified Eagle’s Media (DMEM) 485 
supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 U/mL streptomycin 486 
and 10% foetal bovine serum (FBS) for 72 h in an incubator at 37C and 200 rpm. 487 
 488 
Hybridoma production and mAb purification 489 
Cultures of C. neoformans H99 and C. gattii R265 were microfuged (4000 x g for 5 490 
min) and washed three times in 1 mL Dulbecco’s phosphate-buffered saline (PBS). 491 
Washed cultures were then heat killed for 60 minutes at 65C. Following heat killing 492 
20 L was plated onto YPD to confirm there were no viable cells. Heat-killed H99 493 
and R265 cells were then either lysed (see below) or mixed 1:1 and stored at -20C 494 
prior to inoculation. Fungal cells were lysed using Precellys tubes (UK05 03961-1-495 
004) using programme 6400-2x10-005. Following lysis, lysis beads were microfuged 496 
(3000 x g for 1 min) and supernatant collected. H99 and R265 lysates were mixed 497 
1:1 and stored at -20C. 498 
 499 
BALB/c mice were hyper-immunised with heat-killed H99 and R265 in addition to 500 
their lysates. Hybridomas were generated by a method that has previously been 501 
described (70). NS0 immortal fusion partner cells were fused with splenocytes 502 
mediated by polyethylene glycol (StemCell Technologies). All animal work was 503 
conducted in accordance with Home Office guidelines and following local ethical 504 
approval granted under animal licence 30/2788.  Supernatants from clones were 505 
screened for reactivity with H99 and R265 cells using 96-well plates, with FITC-506 
conjugated anti-mouse IgG and anti-mouse IgM antibodies used to identify positive 507 
clones via epifluorescence microscopy. Positive clone 127 was cultured in RPMI 508 
1640 with IgG-depleted FBS and supernatant collected in a MiniPerm bioreactor 509 
(Sarstedt). MAb Crp127 was purified from supernatant using affinity chromatography 510 
and ProSep Thiosorb (Millipore). 511 
 512 
Hybridoma sequencing and antibody sequence analysis 513 
Sequencing of hybridomas was carried out by Absolute Antibody Ltd (UK). 514 
Sequencing was performed by whole transcriptome shotgun sequencing (RNA-Seq). 515 
In brief, hybridomas were cultured in Iscove’s Modified Dulbecco’s Media (IMDM) 516 
supplemented with 10% FBS in an incubator at 37C and with 5% CO2. Total RNA 517 
was extracted from cells and a barcoded cDNA library generated through RT-PCR 518 
using a random hexamer. Sequencing was performed using an Illumina HiSeq 519 
sequencer. Contigs were assembled and annotated for viable antibody sequences 520 
(i.e those not containing stop codons) to confirm the species and isotype of mAb 521 
Crp127 as murine and IgM, respectively.  522 
 523 
Variable region gene usage was determined using VBASE2 software (71) and CDRs 524 
were predicted using the Kabat numbering system (72). Heavy-chain variable (VH) 525 
and light-chain variable (VL) sequences of mAb Crp127 were aligned with antibody 526 
sequences that have previously been described (40, 73). Amino acid sequences 527 
were aligned using Clustal Omega software (74) and annotated using ESpript 528 
software (75). 529 
 530 
Immunolabelling 531 
Cryptococcus cells were immunostained for flow cytometry and microscopy 532 
experiments. 1 mL of fungal culture was transferred to a 1.5 mL microcentrifuge 533 
tube, microfuged (15,000 x g for 1 min) and washed 3x in PBS. Cell density was 534 
determined using a haemocytometer and adjusted to 107 cells/mL in a final volume 535 
of 200 L. 20 g/mL Crp127, F12D2, 18B7 or mouse anti-human IgG (IgM isotype 536 
control) were added and samples mixed on a rotary wheel at 20 rpm for 1 h at room 537 
temperature. Untreated cells for use in flow cytometry were left untreated. After 538 
primary antibody treatment, samples were microfuged (15,000 x g for 1 min) and 539 
washed 3x in PBS to remove unbound primary antibody. 2 g/mL Alexa-488-540 
conjugated goat anti-mouse IgM (heavy chain) (Thermo Fisher Scientific), Alexa-541 
647-conjugated goat anti-mouse IgM -chain (Abcam) or Alexa-647-conjugated 542 
F(ab')2-Goat anti-Mouse IgG (H+L) (Thermo Fisher Scientific) were added to 543 
antibody-treated samples and samples mixed on a rotary wheel at 20 rpm for 1 h at 544 
room temperature. Secondary antibody was also added to isotype control samples 545 
for flow cytometry. For microscopy experiments, 5 g/mL calcofluor-white (CFW) 546 
was also added at this stage to label chitin.  Following incubation with secondary 547 
antibody, samples were again microfuged (15,000 x g for 1 min) and washed 3x to 548 
remove unbound secondary antibody and CFW. 549 
 550 
Flow cytometry 551 
Flow cytometry experiments were performed with an Attune NxT Flow Cytometer 552 
equipped with an Attune Autosampler (Thermo Fisher Scientific). Untreated, isotype 553 
control and either Crp127 or 18B7 samples were prepared for each strain or 554 
conditions tested. Following immunostaining, samples were diluted to 5 x 106 555 
cells/mL and 200 L of Cryptococcus put into individual wells of a plastic round-556 
bottom 96-well plate ready for insertion into the Attune Autosampler. Sample was 557 
collected from each well at a rate of 100 L/min until 10,000 events were recorded. 558 
The 488 nm laser was used to detect primary antibody bound by Alexa-488-559 
conjugated secondary antibodies, with the same voltage used to power the laser 560 
within each experiment. Flow cytometry data was then analysed using FlowJo (v10) 561 
software. Debris was excluded by using the FSC-A vs. SSC-A gating strategy, 562 
followed by exclusion of doublets using the FSC-A vs. FSC-H gating strategy (fig. 563 
S4). Exclusion of doublets was used to avoid inclusion of cell aggregates that may 564 
happen due to incomplete budding, cell-cell adhesion, or antibody-mediated 565 
agglutination. Where GXM-deficient mutants were analysed, samples were only 566 
gated to exclude debris due to the inseparable large aggregates formed by these 567 
mutants as a result of budding defects. After gating, histograms of fluorescence 568 
intensity were plotted and the median fluorescence intensity (MFI) determined. 569 
Corrected MFI values were calculated by subtracting the MFI value of the mAb-570 
treated sample by the corresponding isotype control sample in the case of Crp127 or 571 
untreated sample where 18B7 was used. Across all experiments, MFI values 572 
returned from isotype control cells were extremely similar to those returned from 573 
untreated cells. 574 
 575 
Confocal microscopy 576 
Following the final washes of the immunostaining procedure, 2 L of stained 577 
cryptococcal cells were spotted onto a glass slide and placed under a square glass 578 
coverslip. Where visualisation of the capsule was necessary, 2 L Indian ink was 579 
also added to the glass slide. Imaging was performed on a Nikon A1R laser 580 
scanning confocal microscope using a 100x object lens and oil immersion. Alongside 581 
transmitted light, 639 nm and 405 nm lasers were used to detect Alexa-647-582 
conjugated secondary antibodies and CFW, respectively. For cells with small 583 
capsules, Z-stacks spanning 8 m were generated using steps of 0.27 m. For 584 
capsule-induced cells, Z-stacks were taken across 20 m using steps of 0.66 m. 585 
Generation of maximum intensity projections (MIPs) and other image processing 586 
was performed using NIS-Elements and ImageJ software. 587 
 588 
Chemical de-O-acetylation of capsular GXM 589 
Where chemical de-O-acetylation of the capsule was required, cells were grown in 590 
YPD broth that had been adjusted pH 11 with NaOH and sterilised with a 0.22 m 591 
filter. Round-bottom culture tubes containing 3 mL of pH 11 YPD broth was then 592 
placed on a rotary wheel turning at 20 rpm for 24 h at 25C. This method was 593 
adapted from that used in a previous study (21). 594 
 595 
Phagocytosis assays 596 
Phagocytosis assays were performed using the murine macrophage-like J774A.1 597 
cell line (mouse BALB/cN; ATCC® TIB-67™). Cells were cultured in DMEM 598 
supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 U/mL streptomycin 599 
and 10% FBS, before 1 x 105 cells were seeded onto round glass coverslips that had 600 
been placed into wells of a flat-bottom 24-well plate and incubated for 24 h at 37C 601 
and 5% CO2. Cells of strain R265 and KN99 were opsonised with 18B7 or Crp127 602 
as described for the first incubation of the immunostaining procedure. In the same 603 
way, cells were opsonised with 10% AB-human serum alone or in combination with 604 
Crp127. To achieve a multiplicity of infection (MOI) of 10, 106 R265 or KN99 cells 605 
were then resuspended in serum-free DMEM and added to each well of J774A.1 606 
cells. Following the infection, each well was gently washed 3x with 1 mL of warmed 607 
PBS to remove extracellular yeast. The contents of each well were then fixed with 608 
4% paraformaldehyde prior to being washed a further 3x. Cover slips were then 609 
extracted from their well, any residual PBS removed by briefly submersing in sterile 610 
dH2O and mounted onto glass slides with Prolong Gold Antifade Mountant (Thermo 611 
Fisher Scientific). The total number of internalised yeast cells per 100 J774A.1 cells 612 
(phagocytic index) was determined by microscopic examination using a Nikon 613 
TE2000-U microscope with a 60x objective lens and oil immersion. 614 
 615 
Capsular swelling reactions 616 
Capsule-induced cells were treated with 50 g/mL Crp127 or 18B7 as described for 617 
the immunostaining procedure. 2 L of Cryptococcus cells were then dropped onto a 618 
glass slide and placed under a square glass coverslip. Imaging was performed on 619 
the differential interference contrast (DIC) channel of a Nikon TE2000-U microscope 620 
using a 60x objective lens with oil immersion. Image processing was performed 621 
using NIS-Elements and ImageJ software. 622 
  623 
Titan cell experiments 624 
Titan cells that exhibit all the properties of in vivo Titan cells were induced in vitro 625 
using a previously described protocol (9). C. neoformans H99, KN99, CBS 8336, 626 
B3501 and C. gattii R265 cells were cultured in glass conical flasks containing 10 mL 627 
yeast nitrogen base (YNB) + 2% glucose at 30C and 200 rpm for 24 h. Cells were 628 
adjusted to an OD600 reading of 0.001 before being transferred into 10% heat-629 
inactivated foetal calf serum (HI-FCS) at a final volume of 3 mL in a plastic six-well 630 
plate and grown for 72 h at 37C and 5% CO2. To begin a culture derived solely from 631 
Titan cells, cells were passed through an 11 m filter, trapping only larger cells on 632 
the filter paper. This filter paper was then washed in PBS to re-suspend Titan cells. 633 
Between 103 and 104 Titan cells were then transferred into 3 mL HI-FCS in a plastic 634 
six-well plate and cultured for a further 72 h at 37C and 5% CO2. Titanising 635 
populations were prepared for imaging according to the method described for 636 
immunostaining. Imaging was performed on a Nikon TE2000-U microscope using a 637 
60x objective lens with oil immersion.  638 
 639 
To quantify the proximity of the Crp127 epitope to the capsule surface, ImageJ 640 
software was used to draw regions of interest (ROIs) around the cell body, the 641 
immunofluorescence binding pattern of the Crp127 and the capsule surface (as 642 
determined by Indian ink staining). For each cell measured, the area of these three 643 
ROIs was determined before the area of the cell body was subtracted from the areas 644 
calculated for both the Crp127 epitope ROI and the capsule surface ROI. Finally, the 645 
area of the Crp127 epitope ROI was divided by the capsule surface ROI as a means 646 
of quantifying the proximity of the Crp127 epitope to the capsule surface. For cells 647 
where no antibody binding was detected, the ratio was scored as 0. A mean number 648 
of 111 and 133 cells were measured per biological replicate for strain H99 and 649 
KN99, respectively. Image processing was performed using NIS-Elements 650 
software. 651 
 652 
Experimental design and statistical analysis 653 
For each experiment described, three biological repeats were performed as 654 
independent experiments that were carried out on different days. All datasets were 655 
analysed using GraphPad Prism 7 or 8 software. 656 
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Fig. 1. Crp127 is an anti-GXM mAb. The ability of Crp127 to bind to GXM- and 956 
GXMGal-deficient mutants of C. gattii and C. neoformans was quantified via flow 957 
cytometry. Scatter plots (top row) and representative histograms (bottom row) are 958 
presented for A) R265 cap10, B) B3501 cap67, C) KN99 cap59, KN99 959 
uge1, KN99 cap59uge1 and their corresponding wild-type strains. For scatter 960 
plots, corrected median fluorescence intensity (MFI) values were calculated by 961 
subtracting the MFI value of isotype control cells from the MFI value of the Crp127-962 
treated cells, with data points representing MFI values calculated from three 963 
biological replicates performed as independent experiments. A Student’s t-test was 964 
used to test for statistically significant differences between R265 cap10 and B3501 965 
cap67 and their corresponding wild-type strains, whilst one-way ANOVA followed 966 
by Dunnett’s multiple comparison test was used to test for statistically significant 967 
differences between KN99 cap59, KN99 uge1cap59, KN99 uge1 and the 968 
wild-type strain KN99 (n=3) (ns P > 0.05; * P < 0.05; ** P < 0.01). Histograms show 969 
a representative distribution of Crp127 binding for one or all of the strains in the 970 
above scatter plot, with the colour-coded key provided for reference. Numerical 971 
values in the top left and right of each histogram correspond to the MFI value 972 
calculated from the strain labelled directly above. D) R265 cap10, E) B3501 973 
cap67, F) KN99 cap59, uge1, uge1cap59 and their wild-type strains were 974 
labelled for chitin using calcofluor-white (CFW; blue) and Crp127 (far-red; goat 975 
Alexa-647-conjugated anti-mouse IgM -chain) and maximum-intensity projections 976 
generated from confocal microscopy z-stacks. Presented are representative images 977 
merged for transmitted light and Crp127 (left panels) and Crp127 and chitin (right 978 
panels). Scale bars represent 5 m.  979 
 980 
 981 
 982 
 983 
 984 
Fig. 2. Crp127 requires O-acetylation, but not xylosylation, of GXM for epitope 985 
recognition. The ability of Crp127 to recognise mutants with specific defects in GXM 986 
modification was quantified via flow cytometry. Scatter plots (top row) and 987 
representative histograms (bottom row) are presented for A) KN99 uxs1, JEC155 988 
uxs1 and corresponding wild-type strains; B) JEC156 cas1 and JEC155 wild-type 989 
and C) KN99 cas3, KN99 cas31 and KN99 wild-type. D) JEC155 uxs1, E) 990 
JEC156 cas1, F) KN99 cas31 and corresponding wild-type strains were labelled 991 
for chitin and Crp127 imaged via confocal microscopy. G) Binding of Crp127 to 992 
chemically deacetylated cells of H99 and B3501 was quantified via flow cytometry 993 
with H) a representative histogram presented for H99. I) Untreated (top) and 994 
chemically deacetylated (bottom) H99 cells were labelled for chitin and Crp127 and 995 
imaged via confocal microscopy. J) Binding of 18B7 to chemically deacetylated cells 996 
of H99 and B3501 was quantified via flow cytometry. K) Representative cells from 997 
the above strains labelled for chitin (blue) and O-acetyl-independent mAb F12D2 998 
(far-red).  For scatter plots, corrected MFI values were calculated by subtracting the 999 
MFI value of isotype control cells from the MFI value of the Crp127- or 18B7-treated 1000 
cells, with data points representing MFI values calculated from three biological 1001 
replicates performed as independent experiments. A Student’s t-test was used to 1002 
test for statistically significant differences between KN99 uxs1, JEC155 uxs1 1003 
and JEC156 cas1 and their corresponding wild-type strain, as well as between 1004 
untreated and chemically deacetylated cells of the same strain (n=3). Dunnet’s 1005 
multiple comparison test was used to test for statistically significant differences 1006 
between KN99 cas3, KN99  cas31 mutants and the KN99  wild-type strain 1007 
(n=3) (ns P > 0.05; * P < 0.05; ** P < 0.01). Histograms show a representative 1008 
distribution of Crp127 or 18B7 binding for one or all of the strains in the above 1009 
scatter plot, with a colour-coded key provided for reference. Numerical values in the 1010 
top left and right of each histogram correspond to the MFI value calculated from the 1011 
strain labelled directly above. Representative maximum intensity projections were 1012 
merged for transmitted light and Crp127 (far-red), and Crp127 and chitin (blue) (right 1013 
panels). Scale bars represent 5 m. 1014 
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Fig. 3. Recognition levels of the Crp127 epitope are associated with serotype. 1042 
The ability of Crp127 to bind to two different strains from each Cryptococcus 1043 
serotypes A, B, C, D and AD was quantified using flow cytometry. A-B) Scatter plots 1044 
show corrected MFI values for each strain, which were calculated by subtracting the 1045 
MFI value of isotype control cells from the MFI value of the corresponding Crp127-1046 
treated cells. Data points represent MFI values calculated from three biological 1047 
replicates performed as independent experiments (n=3). Histograms show a 1048 
representative distribution of Crp127 binding for C) serotype A strains KN99 and 1049 
H99, D) serotype B strains R265 and CDCR272, E) serotype C strains CBS 10101 1050 
and M27055, F) serotype D strains B3501 and JEC155 and G) serotype AD hybrid 1051 
strains CBS 950 and ZG287. Fluorescence intensity values for untreated, isotype 1052 
control and Crp127-treated cells are presented in red, blue and orange, respectively, 1053 
with corresponding MFI values displayed in the top left, centre and right of each 1054 
panel. 1055 
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Fig. 4. The immunofluorescence-binding pattern of Crp127 correlates with 1082 
serotype. Two Cryptococcus strains from A) serotype A (KN99 and H99), B) 1083 
serotype B (R265 and CDCR272), C) serotype C (CBS 10101 and M27055), D) 1084 
serotype D (B3501 and JEC155) and E) serotype AD (CBS 950 and ZG287) were 1085 
labelled for chitin (blue; CFW) and Crp127 (far-red; goat Alexa-647-conjugated anti-1086 
mouse IgM -chain). F) Representative cells from serotype C strains CBS 10101 1087 
and M27055 labelled for chitin (blue) and O-acetyl-independent mAb F12D2 (far-red; 1088 
Alexa-647-conjugated F(ab')2 goat anti-Mouse IgG (H+L)).  Maximum-intensity 1089 
projections were generated via confocal microscopy. Representative images are 1090 
shown for each strain. Images are merged for transmitted light and Crp127 (left 1091 
panels) and Crp127 and chitin (right panels). Scale bars represent 5 m. 1092 
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Fig. 5. Recognition of the Crp127 epitope is largely consistent within C. gattii 1120 
serotypes. The ability of Crp127 to bind to six strains from C. gattii that encompass 1121 
molecular types VGI-VGIIIb was quantified via flow cytometry. A) Scatter plots show 1122 
corrected MFI values for each strain, which were calculated by subtracting the MFI 1123 
value of isotype control cells from the MFI value of the corresponding Crp127-treated 1124 
cells. Data points represent MFI values calculated from three biological replicates 1125 
performed as independent experiments. Tukey’s multiple comparisons test was used 1126 
to test the statistical significance of differences between the six strains (n=3) (ns P > 1127 
0.05; ** P < 0.01; *** P < 0.001). B) Histograms show a representative distribution of 1128 
Crp127 binding for strains DSX (VGI), R265 (VGIIa), CDCR272 (VGIIb), EJB55 1129 
(VGIIc), CA1873 (VGIIIa) and CA1508 (VGIIIb). Fluorescence intensity values for 1130 
untreated, isotype control and Crp127-treated cells are presented in red, blue and 1131 
orange, respectively, with corresponding MFI values displayed in the top left, centre 1132 
and right of each panel. C. gattii strains C) DSX, E) R265, F) CDCR272, G) CA1873 1133 
and H) CA1508 were labelled for chitin (blue; CFW) and Crp127 (far-red; goat Alexa-1134 
647-conjugated anti-mouse IgM -chain) and maximum-intensity projections 1135 
generated via confocal microscopy. Presented are representative images merged for 1136 
transmitted light and Crp127 (left panels) and Crp127 and chitin (right panels). Scale 1137 
bars represent 5 m. 1138 
 1139 
 1140 
 1141 
 1142 
 1143 
 1144 
 1145 
 1146 
 1147 
 1148 
 1149 
 1150 
 1151 
 1152 
 1153 
 1154 
 1155 
 1156 
 1157 
 1158 
 1159 
 1160 
Fig. 6. The Crp127 epitope is spatially confined to distinct capsular regions 1161 
and binding elicits capsular swelling reactions distinct from those of 18B7. 1162 
Cryptococcus cells were grown in capsule-inducing conditions and imaged to 1163 
determine the location of the Crp127 epitope within the enlarged capsule and 1164 
characterise the capsular reaction patterns elicited by this antibody. Cryptococcus 1165 
strains from A) serotype A (KN99 and H99), B) serotype B (R265 and CDCR272, 1166 
C) serotype D (B3501 and JEC155) and D) serotype AD (CBS 950 and ZG287) were 1167 
labelled for chitin (blue; CFW) and Crp127 (far-red; goat Alexa-647-conjugated anti-1168 
mouse IgM -chain), suspended in Indian ink to visualise the capsule and imaged 1169 
using confocal microscopy. Representative images of a single focal plane are shown 1170 
for each strain. Presented are images merged for transmitted light and Crp127 (left 1171 
panels) and Crp127 and chitin (right panels). Capsule-induced cells of strains E) 1172 
KN99, F) R265, G) B3501 and H) CBS 950 were also left untreated (top right 1173 
panels), treated with mAb 18B7 (top right panels) or with mAb Crp127 (bottom 1174 
panels) and imaged using DIC microscopy to observe capsular reaction patterns. 1175 
Scale bars represent 5 m. 1176 
 1177 
 1178 
 1179 
 1180 
 1181 
 1182 
 1183 
 1184 
 1185 
 1186 
 1187 
Fig. 7. Spatial distribution of the Crp127 epitope differs within the capsule of 1188 
the three cell subtypes found in Titanising populations of strain H99, 1189 
suggesting a model of Titanisation-coupled epitope redistribution. Cultures of 1190 
C. neoformans strain H99 that derived solely from Titan cells were investigated for 1191 
differences in the capsular distribution of the Crp127 epitope. A) Representative 1192 
images of cells from strain H99 grown under conditions permissive for Titanisation, 1193 
resulting in formation of Titanide (block arrows and dashed arrows distinguish no 1194 
Crp127 binding and binding, respectively), yeast-like (asterisks) and Titan cells 1195 
(arrowheads). B) A schematic representation of how Crp127 epitope proximity to the 1196 
capsule surface was quantified through the analysis of micrographs using ImageJ. 1197 
Where no antibody binding was detected, the ratio was calculated as 0. C) The 1198 
proximity of the Crp127 epitope to the capsule surface of 2-4 m, 4-10 m and >10 1199 
m cells of strain H99 was quantified. Data points represent all individual cells for 1200 
which the location of the Crp127 epitope was quantified, whilst the horizontal bar 1201 
represents the mean of pooled cells. Red diamonds represent mean values 1202 
calculated from each of three biological repeats. Tukey’s multiple comparisons test 1203 
was used to test for statistically significant differences between the three groups 1204 
(n=3) (** P < 0.01; *** P < 0.001). D) Cell body diameter was plotted against the 1205 
epitope proximity to the capsule surface for all cells measured and from E) cells 4-10 1206 
m in cell body diameter. F) Capsule diameter was plotted against the epitope 1207 
proximity to the capsule surface for cells 4-10 m in cell body diameter.  G) Model 1208 
for Titanisation-coupled redistribution of the Crp127 epitope. Presented are 1209 
representative images of Titanide, yeast-like and Titan cells (top row) of strain H99 1210 
that were recognised by Crp127, in addition to Titanide and yeast-like cells exhibiting 1211 
a second faint ring of antibody binding (white arrows) (bottom row). Scale bars 1212 
represent 5 m. 1213 







